TG Therapeutics (TGTX) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, TG Therapeutics (TGTX) closed at $15.48, marking a -1.46% move from the previous day. This change lagged the S&P 500's daily gain of 0.36%. At the same time, the Dow added 0.01%, and the tech-heavy Nasdaq gained 1.91%.
Prior to today's trading, shares of the biopharmaceutical company had lost 10.07% over the past month. This has lagged the Medical sector's gain of 1.64% and the S&P 500's gain of 1.24% in that time.
TG Therapeutics will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of -$0.36, up 29.41% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $5.41 million, up 167.97% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of -$1.21 per share and revenue of $88.35 million. These totals would mark changes of +17.12% and +3073.4%, respectively, from last year.
It is also important to note the recent changes to analyst estimates for TG Therapeutics. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 1.52% higher. TG Therapeutics is holding a Zacks Rank of #3 (Hold) right now.
The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 151, which puts it in the bottom 41% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
TG Therapeutics, Inc. (TGTX) : Free Stock Analysis Report
